From: Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
 | Placebo | Saxagliptin | p-value |
---|---|---|---|
Retinal capillary flow | Â | Â | Â |
  RCF basal (AU) | 314 ± 14.1 | 288 ± 13.2 | 0.033 |
  RCF flicker (AU) | 331 ± 13.6 | 323 ± 16.8 | 0.462 |
  ∆ (AU) | 16.6 ± 7.9 | 32.8 ± 8.7 | 0.195 |
  ∆ (%) | 6.6 ± 2.2 | 11.4 ± 2.5 | 0.176 |
  RCF pre L-NMMA (AU) | 318 ± 11.3 | 306 ± 13.5 | 0.245 |
  RCF post L-NMMA (AU) | 318 ± 12.8 | 297 ± 13.1 | 0.116 |
  ∆ (AU) | 0.0 ± 6.9 | - 9.0 ± 7.5 | 0.442 |
  ∆ (%) | 0.0 ± 2.1 | - 2.1 ± 2.2 | 0.553 |
Retinal arteriolar structure | Â | Â | Â |
  WLR (-) | 0.38 ± 0.01 | 0.39 ± 0.1 | 0.727 |
  WT (μm) | 14.8 ± 0.5 | 14.8 ± 0.6 | 0.987 |
  Vessel diameter (μm) | 107.7 ± 1.7 | 106.7 ± 2.0 | 0.394 |
  Lumen diameter (μm) | 78.1 ± 1.2 | 77.0 ± 1.4 | 0.256 |
Macrocirculation | Â | Â | Â |
  Central SBP (mmHg) | 124 ± 2.3 | 119 ± 2.3 | 0.038 |
  Central PP (mmHg) | 45.3 ± 2.0 | 41.9 ± 2.0 | 0.058 |
  Central AP (mmHg) | 12.4 ± 0.9 | 11.0 ± 1.0 | 0.094 |
  cAIx@75 (%) | 23.0 ± 1.2 | 21.8 ± 1.3 | 0.212 |
  PWV (m/s) | 8.86 ± 0.26 | 8.56 ± 0.26 | 0.260 |
  UACR (mg/g creatinine) | 5.0 (4.0 – 12.5) | 6.0 (4.0 – 9.0) | 0.285 |